Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
4
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Lambert Eaton Myasthenic Syndrome
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Amifampridine SERB
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
View on EMAFampridine Accord
Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
View on EMAFampyra
Fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale 4-7).
View on EMAFirdapse (previously Zenas)
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
View on EMA